Identifying FLT3 Mutations in AML
Virtual Event: Identifying FLT3 Mutations in Acute Myeloid Leukemia (AML) to Inform Clinical Decision-making – A Focus on Relapsed/Refractory Disease No continuing education (CE) or continuing medical education (CME) credit can be provided for this presentation sponsored by Astellas Pharma US, Inc. PRESENTER *Important note: Attendees are required to view the presented slides during the virtual program To RSVP for this program – Please contact: Melba Vasquez Or go to: https://astellas.virtualspeakercast.net/Registration/index/236 Kindly reply by March 23, 2021 In the RSVP, please include your name, contact information, organization, and specialty. |
|